Global IP Protection: Data Exclusivity Is Top USTR Concern As Licensing Recedes
The U.S. Trade Representative's most recent report on global intellectual property rights suggests compulsory licensing may be receding somewhat as a worry for pharmaceutical companies, but inadequate data protection remains a strong concern
More from Archive
More from Pink Sheet
• By
A new PBM reform package has familiar provisions, but stakeholders want it to move as a stand-alone bill, rather than as part of a larger legislative vehicle.
• By
The European Medicines Agency’s, human medicines committee, the CHMP, is this week poised to issue opinions on potential marketing approvals for 17 products.
• By
The European Medicines Agency is expected to decide whether to recommend EU-wide marketing authorization for six orphan-designated medicines that are all already approved in the US.